Blood test could predict which cancer patients benefit from immunotherapy
NCT ID NCT06116032
Summary
This study aims to identify blood markers that can predict whether cancer patients will respond to FDA-approved immunotherapy treatments. Researchers will follow 1,500 patients receiving treatments like pembrolizumab or nivolumab, tracking their response over six months. The goal is to develop tests that help doctors choose the most effective treatments for each patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.